The Official Website of the Acid Maltase Deficiency Association

It is difficult to say what is impossible for the dreams of yesterday are the hopes of today and the reality of tomorrow. - Robert H. Goddard

Genzyme Pompe Program Update—April 2007

Posted on: April 24, 2007

As many of you are aware, a standard part of the biologics drug development process is to incrementally scale-up manufacturing capacity as demand for the product increases. During the development of Myozyme®, Genzyme began the manufacturing process using a smaller scale, and has since scaled-up to produce larger quantities of product for
commercial use worldwide.  In addition to the use of this larger scale in multiple clinical trials, we’ve successfully transitioned to commercial use of the larger scale of Myozyme in over 29 countries where we have received regulatory approval.  In the United States, we are still in the process of seeking regulatory approval for use of the larger scale
manufacturing process, as it has taken time to produce the necessary data to support the submission to the FDA.

Download complete article

Disclaimer: The AMDA does not endorse any of the products, medications, treatments or information reported herein. The website and its contents is intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.

Address: AMDA PO Box 700248
San Antonio, Texas 78270 USA